On June 9, 2008, Noven Pharmaceuticals, Inc. voluntarily recalled two lots of the Daytrana Methylphenidate Transdermal System. Daytrana is the only transdermal patch approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Noven is recalling the product due to a problem with the release liner removal specifications. Do to the malfunction, patients could have difficulties removing the patch resulting in damage to the product.

Any damaged or hard to remove Daytrana patch should be discarded.

Noven is working with the U.S. Food and Drug Administration to incorporate needed changes to the Daytrana patch.

Defective drug attorneys are working on cases that involve faulty prescription drugs.

This entry was posted on Wednesday, June 11th, 2008 at 12:42 am and is filed under Defective Drugs, Recall. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.